On June 4, Cigna Group rose 4.8% in regular trading, trading at $282.36 per share, with trading volume of $146 million. The rally was driven by the company announcing it will discontinue coverage of GLP-1 weight loss medications under its employee health plan effective July 1.

Cigna stated it will stop reimbursing GLP-1 obesity drugs, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound, for its workforce. The market interpreted this as a positive cost control signal. The company cited increased drug supply and emerging alternatives as the rationale, while clarifying that Type 2 diabetes prescriptions remain unaffected. With approximately 67,700 employees as of year-end, 88% of whom are based in the United States, the discontinuation is expected to meaningfully reduce employee medical plan expenditures.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)